You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmphotericin B
Accession NumberDB00681  (APRD00797)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAmphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Structure
Thumb
Synonyms
Amfotericina B
AMPH-b
Amphotericin B
Amphotéricine B
Amphotericinum B
C-AmB
Liposomal amphotericin b
External Identifiers
  • RP 17774
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbelcetSuspension5 mgIntravenousSigma Tau Pharmaceuticals Inc1997-09-25Not applicableCanada
AmbisomeInjection, powder, lyophilized, for solution50 mg/12.5mLIntravenousAstellas Pharma US, Inc.1997-08-11Not applicableUs
AmbisomePowder, for solution50 mgIntravenousAstellas Pharma Canada Inc2000-05-29Not applicableCanada
AmphotecInjection, lipid complex50 mg/50mgIntravenousKadmon Pharmaceuticals LLC2005-05-202015-12-29Us
AmphotecInjection, lipid complex100 mg/100mgIntravenousKadmon Pharmaceuticals LLC2005-05-202015-12-29Us
Amphotec 100 mgPowder, for suspension100 mgIntravenousThree Rivers Pharmaceuticals Llc2004-06-172013-08-22Canada
Amphotec 50 mgPowder, for suspension50 mgIntravenousThree Rivers Pharmaceuticals Llc2007-02-262013-08-22Canada
Amphotericin B for Injection, USPPowder, for solution50 mgIntravenousSterimax IncNot applicableNot applicableCanada
Fungizone Intravenous Injection 50mgPowder, for solution50 mgIntravenousBristol Myers Squibb Canada1958-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amphotericin BInjection, powder, lyophilized, for solution50 mg/10mLIntravenousX Gen Pharmaceuticals, Inc.1992-04-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbelectCephalon
Ampho-MoronalDermapharm
AmphocilAlza
AmphocinPfizer
AmphotericinBristol-Myers Squibb
FungilinSigma
FungisomeNot Available
FungizoneBristol-Myers Squibb
Fungizone IntravenousBristol-Myers Squibb
HalizonFuji Yakuhin
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Amphotericin B Cholesteryl Sulfate Complex
120895-52-5
ThumbNot applicableDBSALT000993
Categories
UNII7XU7A7DROE
CAS number1397-89-3
WeightAverage: 924.079
Monoisotopic: 923.487849915
Chemical FormulaC47H73NO17
InChI KeyAPKFDSVGJQXUKY-INPOYWNPSA-N
InChI
InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
IUPAC Name
(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid
SMILES
[H][C@]12C[C@@H](O[C@@H]3O[[email protected]](C)[C@@H](O)[[email protected]](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[[email protected]](C)[C@@H](O)[C@@H](C)[[email protected]](C)OC(=O)C[[email protected]](O)C[[email protected]](O)CC[C@@H](O)[[email protected]](O)C[[email protected]](O)C[C@](O)(C[[email protected]](O)[[email protected]]1C(O)=O)O2
Pharmacology
IndicationUsed to treat potentially life threatening fungal infections.
Structured Indications
PharmacodynamicsAmphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Mechanism of actionAmphotericin B is fungistatic or fungicidal depending on the concentration obtained in body fluids and the susceptibility of the fungus. The drug acts by binding to sterols (ergosterol) in the cell membrane of susceptible fungi. This creates a transmembrane channel, and the resultant change in membrane permeability allowing leakage of intracellular components. Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of amphotericin B and the azoles. Amphotericin B, a polyene, binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death.
TargetKindPharmacological actionActionsOrganismUniProt ID
ErgosterolSmall moleculeyes
binder
Candida albicansnot applicabledetails
Related Articles
AbsorptionBioavailability is 100% for intravenous infusion.
Volume of distributionNot Available
Protein bindingHighly bound (>90%) to plasma proteins.
Metabolism

Exclusively renal

Route of eliminationNot Available
Half lifeAn elimination half-life of approximately 15 days follows an initial plasma half-life of about 24 hours.
Clearance
  • 39 +/- 22 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day at Day 1]
  • 17 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day 3-20 days later]
  • 51 +/- 44 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day at Day 1]
  • 22 +/- 15 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day 3-20 days later]
  • 21 +/- 14 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day at Day 1]
  • 11 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day 3-20 days later]
ToxicityOral, rat: LD50 = >5 gm/kg. Amphotericin B overdoses can result in cardio-respiratory arrest.
Affected organisms
  • Various Fungus Species
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Amphotericin B.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Amphotericin B.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with 2-mercaptobenzothiazole.Vet Approved
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Amphotericin B.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Amphotericin B.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Amphotericin B.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin.Approved
AclarubicinAmphotericin B may increase the nephrotoxic activities of Aclarubicin.Investigational
AlclometasoneAlclometasone may increase the hypokalemic activities of Amphotericin B.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amphotericin B.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Amphotericin B.Experimental
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Amphotericin B.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Amphotericin B.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Amphotericin B.Approved, Investigational
AmikacinAmphotericin B may increase the nephrotoxic activities of Amikacin.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Amphotericin B.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amphotericin B.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Amphotericin B.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Amorolfine.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Amrinone.Approved
AmrubicinAmphotericin B may increase the nephrotoxic activities of Amrubicin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Amphotericin B.Approved
AN2690The therapeutic efficacy of Amphotericin B can be decreased when used in combination with AN2690.Investigational
AnecortaveAnecortave may increase the hypokalemic activities of Amphotericin B.Investigational
AnidulafunginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Anidulafungin.Approved, Investigational
annamycinAmphotericin B may increase the nephrotoxic activities of annamycin.Investigational
AnvirzelThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Amphotericin B.Approved
ApramycinAmphotericin B may increase the nephrotoxic activities of Apramycin.Experimental, Vet Approved
ArbekacinAmphotericin B may increase the nephrotoxic activities of Arbekacin.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Amphotericin B.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Artemether.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Amphotericin B.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Azelnidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Amphotericin B.Approved
AzimilideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Azimilide.Investigational
Bafilomycin A1The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Bafilomycin A1.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Amphotericin B.Experimental
BarbitalBarbital may increase the hypotensive activities of Amphotericin B.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Barnidipine.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Amphotericin B.Investigational
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Amphotericin B.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Amphotericin B.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Amphotericin B.Approved
BenidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Benidipine.Approved
Benzoic AcidThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Benzoic Acid.Approved
BepridilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Amphotericin B.Approved
BifonazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Bifonazole.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Amphotericin B.Approved
BortezomibThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Amphotericin B.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amphotericin B.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.Approved, Investigational
BudesonideBudesonide may increase the hypokalemic activities of Amphotericin B.Approved
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amphotericin B.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bupivacaine.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Amphotericin B.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Amphotericin B.Approved, Investigational
ButenafineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Butenafine.Approved
ButoconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Butoconazole.Approved
CaiThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cai.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Amphotericin B.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Amphotericin B.Approved
CandicidinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Candicidin.Withdrawn
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Amphotericin B.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Amphotericin B.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Amphotericin B.Approved, Investigational
CaspofunginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Caspofungin.Approved
CeruleninThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cerulenin.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amphotericin B.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Chloroxine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amphotericin B.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
CiclopiroxThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ciclopirox.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Amphotericin B.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cilnidipine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cinnarizine.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Amphotericin B.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Amphotericin B.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Amphotericin B.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Amphotericin B.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Amphotericin B.Approved
ClotrimazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clozapine.Approved
ColistimethateAmphotericin B may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Amphotericin B.Approved, Investigational
CordycepinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cordycepin.Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Amphotericin B.Approved
CyclosporineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineAmphotericin B may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Amphotericin B.Approved
DarodipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Darodipine.Experimental
DaunorubicinAmphotericin B may increase the nephrotoxic activities of Daunorubicin.Approved
Decanoic AcidThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Decanoic Acid.Experimental
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Amphotericin B.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside.Approved
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Amphotericin B.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Amphotericin B.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Amphotericin B.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Amphotericin B.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amphotericin B.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Amphotericin B.Approved
DidanosineDidanosine can cause a decrease in the absorption of Amphotericin B resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Amphotericin B.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Amphotericin B.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Amphotericin B.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin.Approved
DihydrostreptomycinAmphotericin B may increase the nephrotoxic activities of Dihydrostreptomycin.Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Amphotericin B.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Amphotericin B.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Amphotericin B.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Amphotericin B.Approved
DotarizineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dotarizine.Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Amphotericin B.Approved
DoxorubicinAmphotericin B may increase the nephrotoxic activities of Doxorubicin.Approved, Investigational
DuloxetineAmphotericin B may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Econazole.Approved
EfinaconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Efinaconazole.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Amphotericin B.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Amphotericin B.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Enalaprilat.Approved
EperisoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Eperisone.Approved, Investigational
EpirubicinAmphotericin B may increase the nephrotoxic activities of Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Amphotericin B.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Amphotericin B.Approved
EquileninEquilenin may increase the hypokalemic activities of Amphotericin B.Experimental
EquilinEquilin may increase the hypokalemic activities of Amphotericin B.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Amphotericin B.Approved
EstroneEstrone may increase the hypokalemic activities of Amphotericin B.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Amphotericin B.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amphotericin B.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Amphotericin B.Approved
FelodipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fendiline.Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fimasartan.Approved
fluasteronefluasterone may increase the hypokalemic activities of Amphotericin B.Investigational
FluconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Flucytosine.Approved
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Amphotericin B.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Flunarizine.Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Amphotericin B.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Amphotericin B.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Amphotericin B.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Amphotericin B.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Amphotericin B.Approved
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Amphotericin B.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Amphotericin B.Approved
FormestaneFormestane may increase the hypokalemic activities of Amphotericin B.Approved, Investigational, Withdrawn
FoscarnetFoscarnet may increase the nephrotoxic activities of Amphotericin B.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Amphotericin B.Approved
FosphenytoinThe serum concentration of Amphotericin B can be decreased when it is combined with Fosphenytoin.Approved
FramycetinAmphotericin B may increase the nephrotoxic activities of Framycetin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Amphotericin B.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Gallopamil.Investigational
GeneticinAmphotericin B may increase the nephrotoxic activities of Geneticin.Experimental
GentamicinAmphotericin B may increase the nephrotoxic activities of Gentamicin.Approved, Vet Approved
GENTAMICIN C1AAmphotericin B may increase the nephrotoxic activities of GENTAMICIN C1A.Experimental
GlyphosateThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Glyphosate.Experimental
GriseofulvinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Griseofulvin.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amphotericin B.Approved, Investigational
HaloproginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Haloprogin.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Amphotericin B.Investigational
HexetidineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Hexetidine.Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Amphotericin B.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Amphotericin B.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Amphotericin B.Approved, Vet Approved
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydroflumethiazide.Approved
Hygromycin BAmphotericin B may increase the nephrotoxic activities of Hygromycin B.Vet Approved
IdarubicinAmphotericin B may increase the nephrotoxic activities of Idarubicin.Approved
IloprostThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Amphotericin B.Approved
IndoraminThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Indoramin.Withdrawn
INNO-206Amphotericin B may increase the nephrotoxic activities of INNO-206.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Amphotericin B.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Isoconazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Amphotericin B.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Amphotericin B.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Amphotericin B.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isradipine.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Amphotericin B.Investigational
ItraconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Itraconazole.Approved, Investigational
KanamycinAmphotericin B may increase the nephrotoxic activities of Kanamycin.Approved, Vet Approved
KetoconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Amphotericin B.Approved
LacidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Amphotericin B.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Levobupivacaine.Approved
LevodopaAmphotericin B may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Amphotericin B.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lofexidine.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Amphotericin B.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Amphotericin B.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Amphotericin B.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Amphotericin B.Approved
MedrysoneMedrysone may increase the hypokalemic activities of Amphotericin B.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Amphotericin B.Vet Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Amphotericin B.Approved
MethohexitalMethohexital may increase the hypotensive activities of Amphotericin B.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amphotericin B.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Amphotericin B.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Amphotericin B.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Amphotericin B.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Amphotericin B.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Amphotericin B.Approved, Investigational
MetrizamideAmphotericin B may increase the nephrotoxic activities of Metrizamide.Approved
MevastatinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Mevastatin.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Mibefradil.Withdrawn
MicafunginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Micafungin.Approved, Investigational
MiconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole.Approved, Investigational, Vet Approved
MiltefosineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miltefosine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Amphotericin B.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Amphotericin B.Approved
MometasoneMometasone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
MonensinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Monensin.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Moxonidine.Approved
MyxothiazolThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Myxothiazol.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Amphotericin B.Approved
NaftifineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Naftifine.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Naftopidil.Investigational
NatamycinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Natamycin.Approved
NCX 1022NCX 1022 may increase the hypokalemic activities of Amphotericin B.Investigational
NeamineAmphotericin B may increase the nephrotoxic activities of Neamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Amphotericin B.Approved, Investigational
NeomycinAmphotericin B may increase the nephrotoxic activities of Neomycin.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Amphotericin B.Approved, Investigational
NetilmicinAmphotericin B may increase the nephrotoxic activities of Netilmicin.Approved
NicardipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Amphotericin B.Approved
NifedipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Amphotericin B.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Amphotericin B.Approved
NitroxolineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Nitroxoline.Approved
NystatinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Nystatin.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Obinutuzumab.Approved
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Amphotericin B.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amphotericin B.Approved, Investigational
OuabainThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ouabain.Approved
OxiconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Oxiconazole.Approved
OxprenololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with pafuramidine.Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Amphotericin B.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Amphotericin B.Approved
ParomomycinAmphotericin B may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Amphotericin B.Approved, Investigational
PentamidineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Pentamidine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
PerhexilineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Perhexiline.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Amphotericin B.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Amphotericin B.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Amphotericin B.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amphotericin B.Approved
PimozideAmphotericin B may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pinaverium.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Amphotericin B.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pipamperone.Approved
PirarubicinAmphotericin B may increase the nephrotoxic activities of Pirarubicin.Investigational
PlicamycinAmphotericin B may increase the nephrotoxic activities of Plicamycin.Approved, Withdrawn
PosaconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pramipexole.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Amphotericin B.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Amphotericin B.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Amphotericin B.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pregabalin.Approved, Illicit, Investigational
PregnenolonePregnenolone may increase the hypokalemic activities of Amphotericin B.Experimental
PrenylamineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Amphotericin B.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Amphotericin B.Approved, Investigational
PuromycinAmphotericin B may increase the nephrotoxic activities of Puromycin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amphotericin B.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Amphotericin B.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Amphotericin B.Approved
RadicicolThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Radicicol.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Amphotericin B.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Amphotericin B.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amphotericin B.Approved
RibostamycinAmphotericin B may increase the nephrotoxic activities of Ribostamycin.Approved
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Amphotericin B.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Amphotericin B.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Amphotericin B.Approved
RimexoloneRimexolone may increase the hypokalemic activities of Amphotericin B.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Amphotericin B.Approved
RisedronateThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Risedronate.Approved, Investigational
RisperidoneAmphotericin B may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sacubitril.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Salicylhydroxamic Acid.Experimental
Salicylic acidThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Selegiline.Approved, Investigational, Vet Approved
SertaconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sertaconazole.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sevoflurane.Approved, Vet Approved
SinefunginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sinefungin.Experimental
SirolimusThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sirolimus.Approved, Investigational
SisomicinAmphotericin B may increase the nephrotoxic activities of Sisomicin.Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sodium Nitrite.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Amphotericin B.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Amphotericin B.Approved
SP1049CAmphotericin B may increase the nephrotoxic activities of SP1049C.Investigational
SpectinomycinAmphotericin B may increase the nephrotoxic activities of Spectinomycin.Approved, Vet Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Amphotericin B.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Streptokinase.Approved
StreptomycinAmphotericin B may increase the nephrotoxic activities of Streptomycin.Approved, Vet Approved
StreptozocinAmphotericin B may increase the nephrotoxic activities of Streptozocin.Approved
SucralfateSucralfate can cause a decrease in the absorption of Amphotericin B resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sufentanil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sulconazole.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Amphotericin B.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Amphotericin B.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tamsulosin.Approved, Investigational
TavaboroleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Tavaborole.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Amphotericin B.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Amphotericin B.Approved
TerbinafineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Terconazole.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Thioridazine.Approved
ThymolThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Thymol.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Amphotericin B.Approved
TioconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Tioconazole.Approved
TixocortolTixocortol may increase the hypokalemic activities of Amphotericin B.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amphotericin B.Approved
TobramycinAmphotericin B may increase the nephrotoxic activities of Tobramycin.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolfenamic Acid.Approved
TolnaftateThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Tolnaftate.Approved, Vet Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Amphotericin B.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Amphotericin B.Approved
TranilastThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Amphotericin B.Approved
TrimetrexateThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Trimetrexate.Approved, Investigational
ValrubicinAmphotericin B may increase the nephrotoxic activities of Valrubicin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Amphotericin B.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Vinpocetine.Investigational
VoriconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Voriconazole.Approved, Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Amphotericin B.Approved
ZorubicinAmphotericin B may increase the nephrotoxic activities of Zorubicin.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Frank Sipos, “Process for producing the methyl ester of amphotericin B.” U.S. Patent US4035567, issued March, 1976.

US4035567
General ReferencesNot Available
External Links
ATC CodesJ02AA01A01AB04A07AA07G01AA03
AHFS Codes
  • 08:14.28
PDB EntriesNot Available
FDA labelDownload (1.02 MB)
MSDSDownload (73.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9308
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7539
P-glycoprotein substrateSubstrate0.6404
P-glycoprotein inhibitor INon-inhibitor0.7322
P-glycoprotein inhibitor IINon-inhibitor0.5977
Renal organic cation transporterNon-inhibitor0.9491
CYP450 2C9 substrateNon-substrate0.7992
CYP450 2D6 substrateNon-substrate0.8785
CYP450 3A4 substrateSubstrate0.5496
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.941
CYP450 2D6 inhibitorNon-inhibitor0.9444
CYP450 2C19 inhibitorNon-inhibitor0.921
CYP450 3A4 inhibitorNon-inhibitor0.9381
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.984
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9682
BiodegradationNot ready biodegradable0.9414
Rat acute toxicity2.2357 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9777
hERG inhibition (predictor II)Non-inhibitor0.7887
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apothecon inc div bristol myers squibb
  • Sigma tau pharmaceuticals inc
  • Three rivers pharmaceuticals llc
  • Astellas pharma us inc
  • Abbott laboratories
  • Abraxis pharmaceutical products
  • Teva parenteral medicines inc
  • X gen pharmaceuticals inc
  • Bristol myers squibb co
Packagers
Dosage forms
FormRouteStrength
SuspensionIntravenous5 mg
Injection, powder, lyophilized, for solutionIntravenous50 mg/12.5mL
Powder, for solutionIntravenous50 mg
Injection, lipid complexIntravenous100 mg/100mg
Injection, lipid complexIntravenous50 mg/50mg
Powder, for suspensionIntravenous100 mg
Powder, for suspensionIntravenous50 mg
Injection, powder, lyophilized, for solutionIntravenous50 mg/10mL
Prices
Unit descriptionCostUnit
Ambisome 50 mg vial188.4USD vial
Amphotec 100 mg vial160.0USD vial
Amphotec 50 mg vial93.33USD vial
Fungizone Iv 50 mg/vial72.5USD vial
Amphotericin b powder29.99USD g
Amphotericin b 50 mg vial24.5USD vial
Abelcet 5 mg/ml vial p-f12.0USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1336890 No1995-09-052012-09-05Canada
CA1339008 No1997-03-252014-03-25Canada
US5874104 No1996-02-232016-02-23Us
US5965156 No1996-10-122016-10-12Us
US6406713 No1999-06-182019-06-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point170.0 °CNot Available
water solubility750 mg/L (at 28 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0819 mg/mLALOGPS
logP-0.66ALOGPS
logP-2.3ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.58ChemAxon
pKa (Strongest Basic)9.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count12ChemAxon
Polar Surface Area319.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity244.67 m3·mol-1ChemAxon
Polarizability99.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolides and analogues
Sub ClassNot Available
Direct ParentMacrolides and analogues
Alternative Parents
Substituents
  • Macrolide
  • Glucosamine
  • Amino sugar
  • O-glycosyl compound
  • Glycosyl compound
  • Amino saccharide
  • Beta-hydroxy acid
  • Oxane
  • Monosaccharide
  • Hydroxy acid
  • Dicarboxylic acid or derivatives
  • Secondary alcohol
  • Polyol
  • Lactone
  • Hemiacetal
  • Carboxylic acid ester
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Carboxylic acid
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

1. Ergosterol
Kind
Small molecule
Organism
Candida albicans
Pharmacological action
yes
Actions
binder
References
  1. Laniado-Laborin R, Cabrales-Vargas MN: Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009 Dec 31;26(4):223-7. doi: 10.1016/j.riam.2009.06.003. [PubMed:19836985 ]
  2. Baginski M, Czub J: Amphotericin B and its new derivatives - mode of action. Curr Drug Metab. 2009 Jun;10(5):459-69. [PubMed:19689243 ]
  3. Baginski M, Sternal K, Czub J, Borowski E: Molecular modelling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic. Acta Biochim Pol. 2005;52(3):655-8. Epub 2005 Aug 5. [PubMed:16086075 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:39